Ophthalmic JAK/SYK inhibitor for the eye:
- Dry eye disease is an inflammatory disease that often affects the lacrimal (tear producing) glands of the eye.
- Over five million Americans suffer with this disorder.
- Many patients with chronic dry eye also suffer with autoimmune conditions including systemic lupus erythematosus and rheumatoid arthritis.
- Current treatments include artificial tears as a first line option, then Restasis™ (cyclosporine ophthalmic), an immunosuppressive agent indicated to increase tear production, and subsequently systemic treatments (ie. methotrexate, biologicals).
- Rigel has developed a topical ophthalmic (eye drop) formulation of R348, a JAK/SYK inhibitor, aimed at reducing the inflammation responsible for the symptoms of this disease.
- In December 2012, Rigel initiated a Phase 1 clinical study of R348, as a potential therapeutic for chronic dry eye, and expects to initiate a Phase 2 clinical study in mid 2013.